Download PDF
Aktuelle Rheumatologie 2004; 29(1): 40-49
DOI: 10.1055/s-2004-812963
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Bekannte und neue therapeutische Konzepte der Behandlung der Psoriasis und der Arthritis psoriatica

Well-Known and New Therapeutic Concepts of Psoriasis and Psoriatic ArthritisC. Tomiak1 , W. Miehle1
  • 1Klinik Wendelstein der BfA, Rheumazentrum AHB
Further Information

Publication History

Publication Date:
21 September 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Arthritis psoriatica (A. ps.) fristete lange Zeit ein „Mauerblümchendasein”. Die Bestrebungen, sie als eigene nosologische Entität anzuerkennen, verliefen schleppend und sind letztlich bis heute nicht abgeschlossen. Angesiedelt zwischen chronischer Polyarthritis (Synonym: rheumatoide Arthritis) und den Spondarthritiden sucht die überwiegend mit charakteristischen Hautveränderungen einhergehende chronische Arthritis noch ihren Platz. Die mögliche polyarthritische Verlaufsform sowie Wirbelsäulenmanifestationen und Enthesitiden bilden Gemeinsamkeiten mit den beiden häufigsten rheumatologischen Krankheitsbildern. Alle Bemühungen um ein stichhaltiges therapeutisches Konzept erfolgten bisher „im Windschatten” der chronischen Polyarthritis (c. P.) und der Psoriasis. Zusätzlich erschwerend erscheint, dass die ärztliche Zuständigkeit für die Erkrankung oft nicht eindeutig geklärt ist, was z. B. auch an den unterschiedlichen Bezeichnungen abzulesen ist: Der Dermatologe spricht von der Osteoarthropathia psoriatica oder Psoriasis arthropathica, der Rheumatologe von der Psoriasisarthritis oder Arthritis psoriatica. Internistische Rheumatologen verwenden bevorzugt die Bezeichnung Arthritis psoriatica, da Zeichen der Gelenkentzündung das Krankheitsbild charakterisieren.

Abstract

For a long time, psoriatic arthritis had a “wallflower existence.” Efforts to recognize the disease as a distinct nosologic entity were slow in progress and are still not completed. Allocated somewhere between rheumatoid arthritis and spondyloarthropathies, this disease, which is predominantly associated with characteristic skin lesions, is still searching for its true place. It shares the potential polyarthritic course, axial skeletal involvement and enthesopathic manifestation with both of the most frequent inflammatory rheumatic diseases. All therapeutic concepts were derived from those established in treating rheumatoid arthritis and psoriasis. The search for its place is hampered further by the fact that the right medical specialist is often not consulted. This also reflects the inconsistent terminology: the dermatologist calls it osteoarthritis psoriatica or arthropathic psoriasis and the rheumatologist psoriatic arthritis. As internal medicine-oriented rheumatologists, we prefer the term arthritis psoriatica (psoriasis arthritis) since the arthritic inflammation characterize the clinical manifestation of this disease.

Literatur

  • 1 Abu-Shakra M, Gladman D D, Thorne J C. et al . Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome.  J. Rheumatol. 1995;  22 (2) 241-245
    PubMedGoogle Scholar
  • 2 Antoni C, Kavannaugh A, Kirkham B. et al . The infliximab multinational psoriatic arthritis controlled trial (IMPACT).  Arthritis Rheum. 2002;  46 (985) 381
    PubMedGoogle Scholar
  • 3 Antoni C, Kavanaugh A, Kirkham B. et al . The one year results of Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).  ACR. 2003;  10 Abstract S265-S266
    PubMedGoogle Scholar
  • 4 Brockbank J, Gladman D D. Diagnosis and Management of Psoriatic Arthritis.  Drugs. 2002;  62 (17) 2447-2457
    PubMedGoogle Scholar
  • 5 Cañete J D, Sanmarti R, Marsal S. et al . Antiangiogenic effects of infliximab in synovial tissue in psoriatic arthritis.  ACR. 2003;  10 Abstract S170
    PubMedGoogle Scholar
  • 6 Cauza E, Spak M, Cauza K. et al . Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.  Rheumatol Int. 2002;  22 227-232
    CrossrefPubMedGoogle Scholar
  • 7 Chang D J. A survey of drug effektveness and treatment choices in psoriatic arthritis (Abstr.).  Arthritis Rheum. 1999;  42 (Suppl. 9) 372
    PubMedGoogle Scholar
  • 8 Clegg D, Reda D J, Mejias E. et al . Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative study.  Arthritis Rheum. 1996;  39 (12) 2013-2020
    CrossrefPubMedGoogle Scholar
  • 9 Combe B, Goupille P, Kuntz J L. et al . Sulphasalazine in psoriatic arthritis: A randomized, multicentre, placebo-controlled study.  Br J Rheumatol. 1996;  35 664-668
    PubMedGoogle Scholar
  • 10 Dougados M, van der Linden S, Juhlin R. et al . The European Spondylarthropathy Study Group preliminary criteria for the classification of spondyloarthropathy.  Arthritis Rheum. 1991;  34 1218-1227
    CrossrefPubMedGoogle Scholar
  • 11 Elkayam O, Ophir J, Brener S. et al . Immediate and delayed effects of treatment at the Dead Sea in patients with psoriatic arthritis.  Rheumatol Int. 2000;  19 77-82
    CrossrefPubMedGoogle Scholar
  • 12 Ellis C N, Krueger G G. for the Alefacept Clinical Study Group . Treatment of chronic plaque psoriasis by selective targetting of memory effector T-Lymphocytes.  N Engl J Med. 2001;  345 248-255
    CrossrefPubMedGoogle Scholar
  • 13 Enghard P, Riemekaste G. Regulatorische T-Zellen - ein mögliches Ziel zur Behandlung von systemischen Autoimmunkrankheiten.  Z Rheumatol. 2003;  6 355-360
    PubMedGoogle Scholar
  • 14 Farr M, Kitas G D, Waterhouse L. et al . Sulphasalazine in psoriatic arthritis: a double blind placebo controlled study.  Br J Rheum. 1990;  24 46-49
    PubMedGoogle Scholar
  • 15 Felson D T, Anderson J J, Boers M. et al . Americal College of Rheumatology preliminary definitiions of improvement in rheumatoid arthritis.  Arthritis Rheum. 1995;  38 727-735
    CrossrefPubMedGoogle Scholar
  • 16 Fischer M, Modder G. Radionuclidetherapy of inflammatory joint disease (Abstract).  Nucl Med Commun. 2002;  23 829-831
    CrossrefPubMedGoogle Scholar
  • 17 Fournie B, Crognier L, Arnaud C. et al . Proposed classification criteria of psoriatic arthritis: a preliminary study in 260 patients.  Revue Du Rhumatisme, English edition. 1999;  66 446-456
    PubMedGoogle Scholar
  • 18 Fraser A D, van Kuryk A, Westhovens R. et al . A randomise, double-blind, placebo controlled multi-centre trial of combination therapy with methotrexat plus Ciclosporin vs. Mehtotrexat plus placebo in patients with active psoriatic arthritis (PsA).  ACR. 2003;  10 Abstract 170
    PubMedGoogle Scholar
  • 19 Fredriksson T, Pettersson U. Severe psoriasis: Oral therapy with a new retinoid.  Dermatologica. 1978;  157 238-244
    PubMedGoogle Scholar
  • 20 Geilen C C, Amold M, Orfanos C E. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in II patients.  Br J Dermatol. 2001;  144 583-586
    CrossrefPubMedGoogle Scholar
  • 21 Gladman D D, Farewell V T. Progression in psoriatic arthritis: role of time varying clinical indicators.  J Rheumatol. 1999;  26 2409-2413
    PubMedGoogle Scholar
  • 22 Gladman D D, Hing E N, Schentag C T. et al . Remission in psoriatic arthritis.  J Rheumatol. 2001;  28 (5) 1045-1048
    PubMedGoogle Scholar
  • 23 Gladman D D. Effectiveness of psoriatic arthritis therapies.  Semin Arthritis Rheum. 2003;  33 29-37
    CrossrefPubMedGoogle Scholar
  • 24 Goedkoop A Y, de Rie M A, Kraan M G. et al . Alefacept treatment in psoriatic arthritis: dinical improvement of sldn lesions and arthritis correlates with reduction in CD45RO + T cells in epidermis and synovial tissue.  Br J Dermatol. 2002;  147 1073
    PubMedGoogle Scholar
  • 25 Gorman J D, Kenneth E S, Davis J C. Treatment of ankylosing spondylitis by inhibition of tumor necorsis factor α.  N Engl J Med. 2002;  346 1349
    PubMedGoogle Scholar
  • 26 Gottlieb A B, Vaishnaw A K. Alefacept (Amevive) does not blunt primary or secondary immune responses.  Arthritis Rheum. 2002;  44 S91
    PubMedGoogle Scholar
  • 27 Granstein R D. New treatments for psoriasis.  N Engl J Med. 2001;  345 284-287
    CrossrefPubMedGoogle Scholar
  • 28 Grundman-Kollman M, Mooser G, Schraeder P. et al . Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil.  J Am Acad Dermatol. 2000;  42 835-837
    CrossrefPubMedGoogle Scholar
  • 29 Gupta A K, Grober J S, Hamilton T A. et al . Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled triaI.  J Rheumatol. 1996;  23 (4) 791-792
    PubMedGoogle Scholar
  • 30 Heyendal V, Spuls P I, Opmeer B C. et al . Methotrexate versus Cyclosporine in Moderate-to-severe chronic plaque psoriasis.  N Engl J Med. 2003;  349 658-665
    CrossrefPubMedGoogle Scholar
  • 31 Huscher D, Thiele K, Listing J. et al . The German Collaborative Arthritis Centres, German Rheumatism Research Centre, Berlin: Burden of illness and treatment in psoriatic arthritis compared to rheumatoid arthritis and ankylosing spondylitis in Germany.  ACR. 2003;  10 Abstract 610
    PubMedGoogle Scholar
  • 32 Husted J A, Gladman D D, Farewell V T. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis.  Arthritis Care & Research. 2001;  45 151-158
    CrossrefPubMedGoogle Scholar
  • 33 Husted J, Farewell V, Schentag C T. et al . Changing functional status in patients with psoriatic arthritis: a multistate model approach.  ACR. 2003;  10 Abstract S171
    PubMedGoogle Scholar
  • 34 Jeannou I P, Goupille M. et al . Cervical spine involvement in psoriatic arthritis.  Rev Rhum (Engl. Ed). 1999;  66 (12) 695-700
    PubMedGoogle Scholar
  • 35 Jones S M, Armas J, Cohen M. et al . Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease.  Br J Rheumatol. 1994;  33 834-839
    PubMedGoogle Scholar
  • 36 Jung G. Dermatologie;. Duale Reihe. 4. Auflage Stuttgart; Hippokrates 1998: 377 ff
    Google Scholar
  • 37 Kaltwasser P, Nash P, Gladman D. et al . Leflunomide in the treatment of psoriatic arthritis and psoriasis: Data from a double-blind, randomized, Plazebocontrolled Clinical trial.  Ann Rheum Dis. 2003;  62 (Suppl I) OP 0081-S90
    PubMedGoogle Scholar
  • 38 Kane D, Stefford L, Bresnihan B. et al . A classification study of clinical subsets in an inception cohort with early psoriatic peripheral arthritis: DIP or not DIP revisited.  Rheumatology. 2003;  6 1676-1685
    PubMedGoogle Scholar
  • 39 Kirby B, Fortune D G. et al . The Salford Psoriasis Index: an holistic measure of psoriasis.  Br J Dermatol. 2000;  142 728-732
    CrossrefPubMedGoogle Scholar
  • 40 Kirby B, Richards H L. et al . Physical and psychological measures are necessary to assess overall psoriasis severity.  J Am Acad Dermatol. 2001;  45 72-76
    CrossrefPubMedGoogle Scholar
  • 41 Klinkhoff A, Maksymowych W, Mosher D. et al . The clinical assessement of patients with psoriatica arthritis (PsA): Results of a validation study of the Spondyloarthritis Research Consortium of Canada (SPARCC).  ACR. 2003;  10 Abstract S168
    PubMedGoogle Scholar
  • 42 Krueger J, Kikuchi T, Chamian F. et al . Alefacept selectively targets effector memory and type I T cells, but spares central memory and naive populations.  Br J Dermatol. 2002;  147 1062
    PubMedGoogle Scholar
  • 43 Krueger G, Vaishnaw A K. 987 alefacept (human LFA-3/lgG I fusion protein) is non-immunogenic in two randomized, placebo-controlled phase III trials for chronic plaque psoriasis.  J Allergy Clin Immunol. 2002;  109 320
    PubMedGoogle Scholar
  • 44 Lacaille D, Stein H B, Raboud J. et al . Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?.  J Rheumatol. 2000;  27 1922-1927
    PubMedGoogle Scholar
  • 45 Laiho K, Kauppi M. The cervical spine in patients with psoriatic arthritis.  Ann Rheum Dis. 2002;  61 650-652
    CrossrefPubMedGoogle Scholar
  • 46 Lebwohl M, Tyring S K, Hamilton T K. et al . A Novel Target T-Cell Modulator Efalizumab, for Plaque Psoriasis.  N Engl J Med. 2003;  349 2004-2013
    CrossrefPubMedGoogle Scholar
  • 47 Lewis J S, Ravindran J S, Korendowych E. et al . Prevalence and characteristics of undiagnosed psoriatic arthropathy in psoriasis: a challenge for genetic studies.  Br J Dermatol. 2002;  147 1047-1078
    CrossrefPubMedGoogle Scholar
  • 48 Lewis J S, Ravindran J S, Lovell C. et al . Quiesent sacroiliitis within a psoriatic population.  ACR. 2003;  10 Abstract S170
    PubMedGoogle Scholar
  • 49 Liang G C, Barr W G. Leflunomide for refractory psoriasis and psoriatic arthritis.  J Clin Rheumat. 2001;  7 366-370
    PubMedGoogle Scholar
  • 50 Marguerie L, Flipo R M, Grardel B. et al . Use of disease-modifying anti-rheumatic drugs in patients with psoriatic arthritis.  Bone Spine. 2002;  60 275-281
    PubMedGoogle Scholar
  • 51 Mazzani G, Colini L, DeSabbata G. et al . Methotrexate and cyclosporine combined therapy in severe psoriatic arthritis. A pilot study.  Acta Dermatomyositis Venereol Suppl (Stockh.). 1994;  186 116-117
    PubMedGoogle Scholar
  • 52 McGonagle D, Conaghan P G, Emery P. Psoriatic arthritis: a unified concept twenty years on.  Arthritis Rheum. 1999;  42 1080-1086
    CrossrefPubMedGoogle Scholar
  • 53 Mease P. Etanercept in the treatment of psoriatic arthritis and psoriasis; Power point presentation. www.medscape/com/viewprogramm/256_pnt
    Google Scholar
  • 54 Mease P, Nash P, Gladman D. et al . Leflunomide in the treatment of psoriatic arthritis and psoriasis; joint and skin efficacy and safety in the TOPAS Study.  ACR. 2003;  10 Abstract S169
    PubMedGoogle Scholar
  • 55 Menter A, Evans R, Dooley L T. et al . Infliximab improves signs of plaque psoriasis in patients with psoriatic arthritis.  ACR. 2003;  10 Abstract S168
    PubMedGoogle Scholar
  • 56 Miehle W. Medikamentöse Therapie rheumatischer Erkrankungen. Stuttgart/New York; Thieme 2003
    Google Scholar
  • 57 Miehle W. Arthritis psoriatika. Rheumamed Samerberg 2003
    Google Scholar
  • 58 Ogilvie A L, Antoni C, Dechant C. et al . Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody dears skin lesions of psoriasis resistant to treatment with methotrexate.  Br J Dermatol. 2001;  144 (3) 587-589
    PubMedGoogle Scholar
  • 59 Ohtsuki M, Nakagawa H, Sugai J. et al . Long-term contrinuous versus intermittent cyclosporin therapy for psoriasis.  Dermatol. 2003;  30 290-298
    PubMedGoogle Scholar
  • 60 Olivieri I, Salvarani C, Cantini F. et al . Therapy with cyclosporine in psoriatic arthritis.  Semin Arthritis Rheum. 1997;  27 36-43
    CrossrefPubMedGoogle Scholar
  • 61 Pigatto P D, Gibelli E, Ranza R. et al . Methotrexate in psoriatic polyarthritis.  Acta Derm. Venereol. 1994;  186 (Suppl.) lI4-lI5
    PubMedGoogle Scholar
  • 62 Punzi L, Pianon M, Bertazzolo N. et al . Clinical, laboratory and immunogenetic aspects of posttraumatic psoriatic arthritis: a study of 25 patients.  Clinical and Experimental Rheumatology. 1998;  16 (3) 277-281
    PubMedGoogle Scholar
  • 63 Queiro-Silva R, Torre-Alonso J C, Tinture-Eguren T. et al . A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis.  Ann Rheum Dis. 2003;  62 (I) 68-70
    CrossrefPubMedGoogle Scholar
  • 64 Raffayova H, Rovensky J, Malis F. Treatment with cyclosporine in patients with psoriatic arthritis: results of clinical assessment.  Int J Clin Pharmacol Res. 2000;  20 I-lI
    PubMedGoogle Scholar
  • 65 Savarani C, Cantini F, Olivieri I. et al . Efficacy of infliximab in resistant psoriatic arthritis.  Arthritis Rheum. 2003;  49 541-545
    CrossrefPubMedGoogle Scholar
  • 66 Schräder P, Maser G, Peter R U. et al . Erste Ergebnisse der Therapie der Psoriasisarthritis mit Mycophenolatmofetil.  Z Rheumatol. 2002;  61 545-550
    CrossrefPubMedGoogle Scholar
  • 67 Sparado A, Riccieri V, Sili-Scavalli A. et al . Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.  Clin Exp Rheumatol. 1997;  13 (5) 589-593
    PubMedGoogle Scholar
  • 68 Spuls P I, Bossuyt P MM, van Everdingen J JE. et al . The developement of practice guidelines for the treatment fo severe plaque form psoriasis.  Arch Dermatol. 1998;  134 1591-1596
    CrossrefPubMedGoogle Scholar
  • 69 Tak P P, Maarten C K, Goedkoop A Y. et al . Alefacept therapy reduces the number of effector/memory T cells in psoriasis lesional epidermis.  ACR. 2003;  10 Abstract S168
    PubMedGoogle Scholar
  • 70 Takada K, Dannig C L, Juroiwa T. et al . Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects.  Ann Rheum Dis. 2003;  62 1112-1115
    CrossrefPubMedGoogle Scholar
  • 71 Timonen P, Fried D, Abeywickrama K. et al . Efficacy of low-dose cyclosporin A in psoriasis: results of dosefinding studies.  Br J Dermatol. 1990;  122 33-39
    PubMedGoogle Scholar
  • 72 Ujfalussy I, K06 E, Sesztak M. et al . Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis.  Z Rheumatol. 2003;  62 155-160
    CrossrefPubMedGoogle Scholar

OA Dr. med. C. Tomiak

Klinik Wendelstein der BfA, Rheumazentrum AHB

Kolbermoorer Straße 56

83043 Bad Aibling

Email: klinik-wendelstein@t-online.de

      >